4//SEC Filing
Krause Kevin Michael 4
Accession 0001610717-24-000014
CIK 0001880438other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 6:06 PM ET
Size
20.5 KB
Accession
0001610717-24-000014
Insider Transaction Report
Form 4
Krause Kevin Michael
Chief Strategy Officer
Transactions
- Sale
Common Stock
2024-01-02$20.12/sh−2,583$51,967→ 1,914 total - Exercise/Conversion
Stock Option (right to buy)
2024-01-02−2,583→ 52,285 totalExercise: $0.42Exp: 2030-01-22→ Common Stock (2,583 underlying) - Exercise/Conversion
Common Stock
2024-01-02$0.42/sh+2,583$1,085→ 4,497 total
Footnotes (5)
- [F1]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
- [F2]Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023.
- [F3]Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023.
- [F4]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F5]The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
Documents
Issuer
AN2 Therapeutics, Inc.
CIK 0001880438
Entity typeother
Related Parties
1- filerCIK 0001916925
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 6:06 PM ET
- Size
- 20.5 KB